Skip to main content
| News

Resistell seeking to further develop test to combat antibiotic resistance

26.04.2022

The startup Resistell has launched a study looking into the applicability of a test against antibiotic resistances that is being funded by an independent grant from Pfizer. In so doing, the company from Muttenz in the canton of Basel-Landschaft is seeking to facilitate the continued use of antibiotics in a targeted, precise manner.

The biotech firm Resistell from Muttenz in the canton of Basel-Landschaft has received a grant from the Zurich-based pharmaceutical company Pfizer AG for a research project. For this, the spin-off from the Swiss Federal Institute of Technology Lausanne (EPFL) is seeking to assess the applicability of its antibiotic susceptibility test (AST) against a novel antibiotic, further details of which can be found in a press release. The study aims to provide a proof of concept for the AST developed by Resistell.

According to information from the company itself, a positive outcome in connection with this research project could help to generate a paradigm shift in the management of infectious diseases and open the door to informed, diagnostics-based treatment decisions. “Targeted and precise use of antibiotics is ever more important in the light of constantly increasing multidrug-resistant infections. Resistell’s rapid phenotypic AST enables adequate antibiotic therapy for critically ill patients, which not only saves lives but also extends the lifetime of novel antibiotics that are so scarce nowadays”, explains Danuta Cichocka, CEO of Resistell, in the press release.

Reduction of the test duration

Founded in 2018, Resistell claims to have developed the world’s fastest antibiotic susceptibility test. It is based on the analysis of nano-scale vibrations of living cells. The AST developed by Resistell reduces the duration of a test from what previously took many hours or even days to just a couple of hours. It is hoped that it could help to solve one of the greatest challenges facing the healthcare sector, namely the increasing resistance of pathogens to antibiotics.

Share this article

Sign up to receive our newsletter in your inbox.

You may also be interested in

Gamma Technologies acquires ProFEMAG portfolio
Advanced Manufacturing/AI, Basel Area Business & Innovation, ICT, Innovation, Invest

Gamma Technologies acquires ProFEMAG portfolio

The Basel-based firm ProFEMAG AG has sold its FEMAG software for electrical machine applications to Gamma Technologies. The company based...

Read More
Databaum establishes headquarters in Basel
Basel Area Business & Innovation, ICT, Innovation, Invest, Life Sciences / biotech

Databaum establishes headquarters in Basel

Databaum is establishing its headquarters in Basel and plans to grow from its location there. The startup provides the agricultural...

Read More
Clinerion launches patient information platform
Basel Area Business & Innovation, Digital Health, ICT, Innovation, Invest, Life Sciences / biotech

Clinerion launches patient information platform

Basel-based Clinerion is introducing its machine learning platform. It comprises a global network of hospitals and enables researchers to recognize...

Read More
New innovation campus opens in the Basel Area
Basel Area Business & Innovation, Innovation, Invest, Life Sciences / biotech, Switzerland Innovation Park

New innovation campus opens in the Basel Area

The Main Campus of the Switzerland Innovation Park Basel Area was officially opened on October 29. In his speech, Federal...

Read More
Sumitovant acquires all shares in Myovant
Basel Area Business & Innovation, Innovation, Invest, Life Sciences / biotech

Sumitovant acquires all shares in Myovant

Sumitovant is in the process of making Basel-based Myovant Sciences a wholly owned subsidiary by acquiring a 100 percent shareholding...

Read More
VectivBio raises 125 million US dollars in stock sale
Basel Area Business & Innovation, Innovation, Invest, Life Sciences / biotech

VectivBio raises 125 million US dollars in stock sale

VectivBio has announced the closing of the subscription offer for 16,700,000 ordinary shares. The Basel-based biotechnology firm has generated gross...

Read More
1 2 3 29

Do you have a question? We'd like to hear from you.